Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>Products>This Product
  Products


POLARstar Optima Multimode Plate Reader with FP

Product Description
polarstar-optima.jpg

The POLARstar OPTIMA is a full multimode microplate reader which incorporates Simultaneous Dual Emission detection for fluorescent polarization. The POLARstar OPTIMA offers five different measurement principles:

• Fluorescence Polarization
• Fluorescence Intensity - including FRET
• Time-Resolved Fluorescence - including DELFIA®
• High-Performance Luminescence (flash and glow)- including BRET
• Absorbance - UV/Vis with path length correction

The POLARstar OPTIMA is designed for the widest possible range of non-radioactive labeled applications:

• Ca2+ Measurements (e.g. Ca2+Flux with Fura-2 or Indo-1)
• Molecular Interactions
• Enzyme Activity
• Cell Toxicity, Proliferation and Viability
• ATP Quantification
• Immunoassays
• Kinase, cAMP, and other second messenger signaling
• DNA/RNA quantification
• GFP and other fluorescent protein cell-based assays
• And many more…

The POLARstar OPTIMA is a multimode microplate reader that covers the wavelength range from 240 – 740 nm (900 nm optional). The POLARstar OPTIMA reads all plate formats from 6- up to 384-well. Top and bottom reading are standard, and the dual-channel detection system can be used for fluorescence polarization as well as dual emission wavelength measurements like FRET or BRET. Incubation up to 45°C or 60°C, gas vent connection, up to two built-in reagent injectors, fast filter wheels, and the ability to define up to 8 sets of filters are just some of the outstanding features found in the POLARstar OPTIMA.

Complete Software Package
The POLARstar OPTIMA comes with BMG LABTECH's established OPTIMA Reader Control Software and comprehensive MARS Data Analysis Software. The familiar and highly visual OPTIMA reader control software provides limitless possibilities for test set up and is fully compliant with FDA regulation 21 CFR Part 11. The well-organized Data Analysis Software – MARS – offers a Template Manager for building complex data processing protocols and a Wizard-guided interface to create easy step-by-step calculations, and much more.
Product POLARstar Optima Multimode Plate Reader with FP
Company BMG Labtech GmbH
Price Request a quote
More Information View company product page
Catalog Number Unspecified
Quantity Unspecified
Company Logo

BMG Labtech GmbH
Allmendgruen 8, 77799 Ortenberg Germany

Tel: +49 781 96968-0
Fax: +49 781 96968-67
Email: hts@bmglabtech.com



Scientific News
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
Improving Engineered T-Cell Cancer Treatment
Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list."

SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!